Antisense technology: From unique laboratory tool to novel anticancer treatments

From Nucleic Acids Sequences to Molecular Medicine

Volumn , Issue , 2012, Pages 145-189

  Di Cresce, Christine ^a,b   Way, Colin ^a,b   Rytelewski, Mateusz ^a,b   Vareki, Saman Maleki ^a,b   Nilam, Supritha ^a   Vincent, Mark D ^a,b   Koropatnick, James ^a,b   Ferguson, Peter J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Anticancer drug therapeutic; Antisense; Oligodeoxynucleotide(s); RNA interference; Synthetic lethality

Indexed keywords

EID: 84875132756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-27426-8_7     Document Type: Chapter

References (268)

1. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75-86
2. Abbott DW, Freeman ML, Holt JT (1998) Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978-985
3. Acsadi G, Dickson G, Love DR et al (1991) Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352:815-818
4. Adjei AA, Dy GK, Erlichman C et al (2003) A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 9:115-123
5. Advani R, Peethambaram P, Lum BL et al (2004) A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100:321-326
6. Agrawal S (1999) Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta 1489:53-68
7. Aigner A (2006) Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol 124:12-25
8. Akinc A, Zumbuehl A, Goldberg M et al (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26:561-569
9. Alam MR, Ming X, Fisher M et al (2011) Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem 22:1673-1681
10. Alberts SR, Schroeder M, Erlichman C et al (2004) Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 22:4944-4950
11. Alvarez-Salas LM (2008) Nucleic acids as therapeutic agents. Curr Top Med Chem 8:1379-1404
12. Aly A, Ganesan S (2011) BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 3:66-74
13. Ambegia E, Ansell S, Cullis P et al (2005) Stabilized plasmid-lipid particles containing PEG- diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 1669:155-163
14. Anderson VE, Walton MI, Eve PD et al (2011) CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 71:463-472
15. Arechavala-Gomeza V, Graham IR, Popplewell LJ et al (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18:798-810
16. Bai J, Yokoyama K, Kinuya S et al (2004) In vitro detection of mdr1 mRNA in murine leukemia cells with 111In-labeled oligonucleotide. Eur J Nucl Med Mol Imaging 31:1523-1529
17. Baldwin A, Grueneberg DA, Hellner K et al (2010) Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA 107:12463-12468
18. Barbie DA, Tamayo P, Boehm JS et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112
19. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
20. Bauzon F, Zhu L (2010) Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality. Cell Cycle 9:2118-2123
21. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259-293
22. Berg RW, Ferguson PJ, Vincent MD et al (2003) A “combination oligonucleotide” antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther 10:278-286
23. Bertrand JR, Pottier M, Vekris A et al (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296:1000-1004
24. Biswas S, Dodwadkar NS, Sawant RR et al (2011) Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization. Bioconjug Chem 22:2005-2013
25. Boeckle S, von Gersdorff K, van der Piepen S et al (2004) Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 6:1102-1111
26. Bogdahn U, Hau P, Stockhammer G et al (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase Ilb study. Neuro Oncol 13:132-142
27. Bonci D, Coppola V, Musumeci M et al (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14:1271-1277
28. Breaker RR, Joyce GF (1994) A DNA enzyme that cleaves RNA. Chem Biol 1:223-229
29. Brough R, Frankum JR, Costa-Cabral S et al (2011) Searching for synthetic lethality in cancer. Curr Opin Genet Dev 21:34-41
30. Bruserud O (2007) Introduction: RNA and the treatment of human cancer. Curr Pharm Biotechnol 8:318-319
31. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917
32. Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77-93
33. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866
34. Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801
35. Carroll JB, Warby SC, Southwell AL et al (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19:2178-2185
36. Carter BZ, Mak DH, Morris SJ et al (2011) XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34 + 38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16:67-74
37. Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655
38. Cerritelli SM, Crouch RJ (2009) Ribonuclease H: the enzymes in eukaryotes. FEBS J 276:1494-1505
39. Cerutti H (2003) RNA interference: traveling in the cell and gaining functions? Trends Genet 19:39-46
40. Chan DA, Giaccia AJ (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 10:351-364
41. Chanan-Khan AA, Niesvizky R, Hohl RJ et al (2009) Phase III randomised study of dexametha- sone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50:559-565
42. Chen X, Zhong S, Zhu X et al (2008) Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res 68:3169-3177
43. Chen X, Wang X, Wang Y et al (2010a) Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145:17-25
44. Chen S, Blank JL, Peters T et al (2010b) Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 70:4318-4326
45. Cheng CJ, Saltzman WM (2011) Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 32:6194-6203
46. Chi KN, Zoubeidi A, Gleave ME (2008a) Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 17:1955-1962
47. Chi KN, Siu LL, Hirte H et al (2008b) A phase I study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14:833-839
48. Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254
49. Chia S, Dent S, Ellard S et al (2009) Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 15:708-713
50. Cho HY, Srinivasan A, Hong J et al (2011) Synthesis of biocompatible PEG-based star polymers with cationic and degradable core for siRNA delivery. Biomacromolecules 12:3478-3486
51. Cirak S, Arechavala-Gomeza V, Guglieri M et al (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595-605
52. Cirak S, Feng L, Anthony K et al (2012) Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 20:462-467
53. Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136:777-793
54. Coppelli FM, Grandis JR (2005) Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr Pharm Des 11:2825-2840
55. Coudert B, Anthoney A, Fiedler W et al (2001) Phase II trial with ISIS 5132 inpatients with smallcell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) early clinical studies group report. Eur J Cancer 37:2194-2198
56. Cripps MC, Figueredo AT, Oza AM et al (2002) Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 8:2188-2192
57. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704-714
58. Crooke ST (1998) Vitravene—another piece in the mosaic. Antisense Nucleic Acid Drug Dev 8: vii-viii
59. Crooke ST, Vickers T, Lima W et al (2007) In: Crooke ST (ed) Antisense drug technology: principles, strategies and applications. Taylor & Francis Group, Boca Raton, FL, pp 5-46
60. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodex- trin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659-668
61. Davis ME, Zuckerman JE, Choi CH et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070
62. De Clercq E (2004) Antiviral drugs in current clinical use. J Clin Virol 30:115-133
63. de Fougerolles AR (2008) Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19:125-132
64. Dean E, Jodrell D, Connolly K et al (2009) Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 27:1660-1666
65. Dedes KJ, Wetterskog D, Ashworth A et al (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8:261-271
66. Di Cresce C, Koropatnick J (2010) Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets 10:555-565
67. Di Cresce C, Figueredo R, Ferguson PJ et al (2011) Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5- fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther 338:952-963
68. Dong Y, Li A, Wang J et al (2010) Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res 70:5465-5474
69. Duchaine TF, Slack FJ (2009) RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 16:61-66
70. Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457-467
71. Eguchi T, Takaki T, Itadani H et al (2007) RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 26:509-520
72. Evers B, Helleday T, Jonkers J (2010) Targeting homologous recombination repair defects in cancer. Trends Pharmacol Sci 31:372-380
73. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921
74. Feliciano A, Sanchez-Sendra B, Kondoh H et al (2011) MicroRNAs regulate key effector pathways of senescence. J Aging Res 2011:205-378
75. Feng Z, Scott SP, Bussen W et al (2011) Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci USA 108:686-691
76. Ferguson PJ, DeMoor JM, Vincent MD et al (2001) Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br J Pharmacol 134:1437-1446
77. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885
78. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391:806-811
79. Fischer D, Bieber T, Li Y et al (1999) A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 16:1273-1279
80. Flynn J, Berg RW, Wong T et al (2006) Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol Cancer Ther 5:1423-1433
81. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134
82. Fu P, Shen B, Zhao C et al (2010) Molecular imaging of MDM2 messenger RNA with 99mTc- labeled antisense oligonucleotides in experimental human breast cancer xenografts. J Nucl Med 51:1805-1812
83. Ganesan S, Silver DP, Greenberg RA et al (2002) BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111:393-405
84. Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5:381-391
85. Geary RS, Watanabe TA, Truong L et al (2001) Pharmacokinetic properties of 2’-O-(2- methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897
86. Geary RS, Yu RZ, Watanabe T et al (2003) Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 20-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419-1428
87. Geary RS, Bradley JD, Watanabe T et al (2006) Lack of pharmacokinetic interaction for ISIS 113715, a 20-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 45:789-801
88. Gleave M, Jansen B (2003) Clusterin and IGFBPs as antisense targets in prostate cancer. Ann NY Acad Sci 1002:95-104
89. Gollob J, Infante, JR, Shapiro G et al (2010) Interim safety and pharmacodynamic results for ALN- VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 28 (suppl): abstr 3042
90. Golzio M, Mazzolini L, Paganin-Gioanni A et al (2009) Targeted gene silencing into solid tumors with electrically mediated siRNA delivery. Methods Mol Biol 555:15-27
91. Grimm D, Kay MA (2007) Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 15:878-888
92. Grunweller A, Wyszko E, Bieber B et al (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2’-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31:3185-3193
93. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
94. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
95. Hartwell LH, Szankasi P, Roberts CJ et al (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278:1064-1068
96. Hayashita Y, Osada H, Tatematsu Y et al (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65:9628-9632
97. Herrero MA, Toma FM, Al-Jamal KT et al (2009) Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. J Am Chem Soc 131:9843-9848
98. Higuchi Y, Kawakami S, Hashida M (2010) Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24:195-205
99. Hockenbery D, Nunez G, Milliman C et al (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336
100. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919-928
101. Hossini AM, Eberle J, Fecker LF et al (2003) Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett 553:250-256
102. Intra J, Salem AK (2008) Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release 130:129-138
103. Ivanova G, Arzumanov A, Gait MJ et al (2007) Comparative studies of tricyclo-DNA- and LNA- containing oligonucleotides as inhibitors of HIV-1 gene expression. Nucleosides Nucleotides Nucleic Acids 26:747-750
104. Izant JG, Weintraub H (1984) Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 36:007-1015
105. Jachimczak P, Bogdahn U, Schneider J et al (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78:944-951
106. Jaschinski F, Rothhammer T, Jachimczak P et al (2011) The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Curr Pharm Biotechnol 12:2203-2213
107. Jason TL, Koropatnick J, Berg RW (2004) Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 201:66-83
108. Jason TL, Figueredo R, Ferguson PJ et al (2008) ODN 491, a novel antisense oligodeoxynu- cleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines. DNA Cell Biol 27:229-240
109. Jiang H, Reinhardt HC, Bartkova J et al (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23:1895-1909
110. Juliano R, Alam MR, Dixit V et al (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36:4158-4171
111. Kaina B, Margison GP, Christmann M (2010) Targeting O-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 67:3663-3681
112. Kairemo KJ, Tenhunen M, Jekunen AP (1996a) Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data. Antisense Nucleic Acid Drug Dev 6:215-220
113. Kairemo KJ, Tenhunen M, Jekunen AP (1996b) Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates. Anticancer Drug Des 11:439-449
114. Kairemo KJ, Tenhunen M, Jekunen AP (1998) Gene therapy using antisense oligodeoxynu- cleotides labeled with Auger-emitting radionuclides. Cancer Gene Ther 5:408-412
115. Kairemo KJ, Jekunen AP, Tenhunen M (2000) Dosimetry and optimization of in vivo targeting with radiolabeled antisense oligodeoxynucleotides: oligonucleotide radiotherapy. Methods Enzymol 314:506-524
116. Kam NW, Liu Z, Dai H (2005) Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 127:12492-12493
117. Kamimura K, Suda T, Xu W et al (2009) Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. Mol Ther 17:491-499
118. Kelland L (2006) Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs 15:1309-1318
119. Kim K, Lee YS, Carthew RW (2007) Conversion of pre-RISC to holo-RISC by Ago2 during assembly of RNAi complexes. RNA 13:22-29
120. Kinali M, Arechavala-Gomeza V, Feng L et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918-928
121. Knox JJ, Chen XE, Feld R et al (2008) A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs 26:193-194
122. Koller E, Vincent TM, Chappell A et al (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795-4807
123. Koslowsky I, Shahhosseini S, Mirzayans R et al (2011) Evaluation of an 18F-labeled oligonucleotide probe targeting p21(WAF1) transcriptional changes in human tumor cells. Oncol Res 19:265-274
124. Kota J, Chivukula RR, O’Donnell KA et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017
125. Krendel M, Zenke FT, Bokoch GM (2002) Nucleotide exchange factor GEF-H1 mediates crosstalk between microtubules and the actin cytoskeleton. Nat Cell Biol 4:294-301
126. Kuijpers WH, Bos ES, Kaspersen FM et al (1993) Specific recognition of antibody- oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two- step radioimmunotherapy of cancer. Bioconjug Chem 4:94-102
127. Kumar MS, Lu J, Mercer KL et al (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39:673-677
128. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628-1644
129. LaCasse EC, Cherton-Horvat GG, Hewitt KE et al (2006) Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 12:5231-5241
130. Lai SY, Koppikar P, Thomas SM et al (2009) Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 27:1235-1242
131. Lee H, Trainer AH, Friedman LS et al (1999) Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell 4:1-10
132. Lee Y, Lee SH, Kim JS et al (2011) Controlled synthesis of PEI-coated gold nanoparticles using reductive catechol chemistry for siRNA delivery. J Control Release 155:3-10
133. Lehto T, Simonson OE, Mager I et al (2011) A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 19:1457-1467
134. Lennox KA, Behlke MA (2011) Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther 18:1111-1120
135. Leonetti C, Zupi G (2007) Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy. Curr Pharm Des 13:463-470
136. Leung M, Rosen D, Fields S et al (2011) Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 17:854-862
137. Lewis DL, Wolff JA (2005) Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol 392:336-350
138. Lewis DL, Hagstrom JE, Loomis AG et al (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32:107-108
139. Lin H, Dai T, Xiong H et al (2010) Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One 5:e15797
140. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258-1266
141. Lord CJ, McDonald S, Swift S et al (2008) A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7:2010-2019
142. Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838
143. Lu Y, Xiao J, Lin H et al (2009) A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 37:e24
144. Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848
145. Maclean KH, Dorsey FC, Cleveland JL et al (2008) Targeting lysosomal degradation induces p53- dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118:79-88
146. Mansoor M, Melendez AJ (2008) Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Biol 2:275-295
147. Marshall JL, Eisenberg SG, Johnson MD et al (2004) A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer 4:268-274
148. Martello G, Rosato A, Ferrari F et al (2010) A microRNA targeting dicer for metastasis control. Cell 141:1195-1207
149. Martin SA, McCarthy A, Barber LJ et al (2009) Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 1:323-337
150. Martin SA, McCabe N, Mullarkey M et al (2010) DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17:235-248
151. Martin SA, Hewish M, Sims D et al (2011) Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair- deficient cancers. Cancer Res 71:1836-1848
152. Marwick C (1998) First “antisense” drug will treat CMV retinitis. JAMA 280:871
153. Matsubara H, Takeuchi T, Nishikawa E et al (2007) Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 26:6099-6105
154. McCabe N, Turner NC, Lord CJ et al (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115
155. McCaffrey AP, Meuse L, Pham TT et al (2002) RNA interference in adult mice. Nature 418:38-39
156. McNamara JO 2nd, Andrechek ER, Wang Y et al (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005-1015
157. Meister G, Landthaler M, Patkaniowska A et al (2004a) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15:185-197
158. Meister G, Landthaler M, Dorsett Y et al (2004b) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544-550
159. Mendes-Pereira AM, Martin SA, Brough R et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315-322
160. Michels S, Schmidt-Erfurth U, Rosenfeld PJ (2006) Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs 15:779-793
161. Miyake H, Nelson C, Rennie PS et al (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60:170-176
162. Miyake H, Hara I, Kamidono S et al (2003) Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 10:469-473
163. Mizuarai S, Irie H, Schmatz DM et al (2008) Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med 8:774-783
164. Mizuarai S, Yamanaka K, Itadani H et al (2009) Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 8:34
165. Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90-95
166. Moreira JN, Santos A, Simoes S (2006) Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 1:217-235
167. Morgan-Lappe S, Woods KW, Li Q et al (2006) RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 25:1340-1348
168. Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007
169. Mu P, Nagahara S, Makita N et al (2009) Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978-2990
170. Mukai H, Kawakami S, Hashida M (2008) Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochem Biophys Res Commun 372:383-387
171. Mukai H, Kawakami S, Kamiya Y et al (2009) Pressure-mediated transfection of murine spleen and liver. Hum Gene Ther 20:1157-1167
172. Mukai H, Kawakami S, Takahashi H et al (2010) Key physiological phenomena governing transgene expression based on tissue pressure-mediated transfection in mice. Biol Pharm Bull 33:1627-1632
173. Mulholland P (2011) “A trial looking at Trabedersen (AP12009) for anaplastic astrocytoma that has come back after treatment or continued to grow during treatment (SAPPHIRE).” from http://cancerhelp.cancerresearchuk.org/trials/a-trial-Trabedersen-AP12009-anaplastic-astrocytoma-come-back-after-treatment-or-continued-grow-during-treatment
174. Muntoni F, Wood MJ (2011) Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov 10:621-637
175. Muratovska A, Eccles MR (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558:63-68
176. Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319
177. Nghiem P, Park PK, Kim Y et al (2001) ATR inhibition selectively sensitizes G1 checkpoint- deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 98:9092-9097
178. Nickoloff BJ, Hendrix MJ, Pollock PM et al (2005) Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 10:95-104
179. Nijman SM (2011) Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 585:1-6
180. O’Brien SM, Cunningham CC, Golenkov AK et al (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702
181. O’Brien S, Moore JO, Boyd TE et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25:1114-1120
182. O’Brien S, Moore JO, Boyd TE et al (2009) 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27:5208-5212
183. O’Connor R (2009) A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance. Curr Cancer Drug Targets 9:273-280
184. O’Rourke JR, Swanson MS (2009) Mechanisms of RNA-mediated disease. J Biol Chem 284:7419-7423
185. Oh YK, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61:850-862
186. Olivares J, Kumar P, Yu Y et al (2011) Phase I trial of TGF-{beta}2 antisense GM-CSF gene- modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 17:183-192
187. Oza AM, Elit L, Swenerton K et al (2003) Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol Oncol 89:129-133
188. Paganin-Gioanni A, Bellard E, Escoffre JM et al (2011) Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells. Proc Natl Acad Sci USA 108:10443-10447
189. Pandyra AA, Berg R, Vincent M et al (2007) Combination silencer RNA (siRNA) targeting Bcl- 2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. J Pharmacol Exp Ther 322:123-132
190. Pasquinelli AE, Hunter S, Bracht J (2005) MicroRNAs: a developing story. Curr Opin Genet Dev 15:200-205
191. Paterson BM, Roberts BE, Kuff EL (1977) Structural gene identification and mapping by DNA- mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74:4370-4374
192. Paz-Ares L, Douillard JY, Koralewski P et al (2006) Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24:1428-1434
193. Plummer R (2010) Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 16:4527-4531
194. Prato M, Kostarelos K, Bianco A (2008) Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 41:60-68
195. Puyol M, Martin A, Dubus P et al (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63-73
196. Rayburn ER, Zhang R (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13:513-521
197. Rayburn ER, Wang H, Zhang R (2006) Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 11:337-352
198. Rehman FL, Lord CJ, Ashworth A (2010) Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 7:718-724
199. Reinhardt HC, Aslanian AS, Lees JA et al (2007) p53-deficient cells rely on ATM- and ATR- mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11:175-189
200. Ren Y, Li R, Zheng Y et al (1998) Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases. J Biol Chem 273:34954-34960
201. Rizzi F, Coletta M, Bettuzzi S (2009) Chapter 2: Clusterin (CLU): from one gene and two transcripts to many proteins. Adv Cancer Res 104:9-23
202. Roberts J, Palma E, Sazani P et al (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 14:471-475
203. Rottmann S, Wang Y, Nasoff M et al (2005) A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci USA 102:15195-15200
204. Ruzankina Y, Schoppy DW, Asare A et al (2009) Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet 41:1144-1149
205. Rychahou PG, Evers BM (2010) Hydrodynamic delivery protocols. Methods Mol Biol 623:189-195
206. Saad F, Hotte S, North S et al (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17:5765-5773
207. Saleh M, Posey J, Pleasant L et al (2000) A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 19:abstr 1258
208. Sanguino A, Lopez-Berestein G, Sood AK (2008) Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem 8:248-255
209. Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226
210. Sarthy AV, Morgan-Lappe SE, Zakula D et al (2007) Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 6:269-276
211. Satkauskas S, Bureau MF, Mahfoudi A et al (2001) Slow accumulation of plasmid in muscle cells: supporting evidence for a mechanism of DNA uptake by receptor-mediated endocytosis. Mol Ther 4:317-323
212. Schafer J, Hobel S, Bakowsky U et al (2010) Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials 31:6892-6900
213. Schimmer AD, Herr W, Hanel M et al (2011) Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk 11:433-438
214. Schlingensiepen R, Goldbrunner M, Szyrach MN et al (2005) Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15:94-104
215. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A et al (2006) Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev 17:129-139
216. Scholl C, Frohling S, Dunn IF et al (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834
217. Segura MF, Hanniford D, Menendez S et al (2009) Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 106:1814-1819
218. Sewell KL, Geary RS, Baker BF et al (2002) Phase I trial of ISIS 104838, a 2’-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343
219. Shaheen M, Allen C, Nickoloff JA et al (2011) Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 117:6074-6082
220. Shannan B, Seifert M, Leskov K et al (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13:12-19
221. Sharp PA (2009) The centrality of RNA. Cell 136:577-580
222. Shi Y, Gera J, Hu L et al (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034
223. Sonoke S, Ueda T, Fujiwara K et al (2008) Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 68:8843-8851
224. Stavropoulou V, Brault L, Schwaller J (2010) Insights into molecular pathways for targeted therapeutics in acute leukemia. Swiss Med Wkly 140:w13068
225. Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents—is the bullet really magical? Science 261:1004-1012
226. Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 48:2659-2668
227. Stenvang J, Kauppinen S (2008) MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther 8:59-81
228. Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75:285-288
229. Suda T, Suda K, Liu D (2008) Computer-assisted hydrodynamic gene delivery. Mol Ther 16:1098-1104
230. Summerton J (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489:141-158
231. Sur S, Pagliarini R, Bunz F et al (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106:3964-3969
232. Sutphin PD, Chan DA, Li JM et al (2007) Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 67:5896-5905
233. Takamizawa J, Konishi H, Yanagisawa K et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756
234. Takei Y, Nemoto T, Mu P et al (2008) In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7:211-221
235. Takeshita F, Minakuchi Y, Nagahara S et al (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102:12177-12182
236. Tamm I, Wagner M (2006) Antisense therapy in clinical oncology: preclinical and clinical experiences. Mol Biotechnol 33:221-238
237. Trougakos IP, Lourda M, Antonelou MH et al (2009) Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res 15:48-59
238. Turcotte S, Chan DA, Sutphin PD et al (2008) A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 14:90-102
239. Tutt A, Robson M, Garber JE et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
240. Urban-Klein B, Werth S, Abuharbeid S et al (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-466
241. Usman N, Blatt LM (2000) Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 106:1197-1202
242. Varkouhi AK, Mountrichas G, Schiffelers RM et al (2012) Polyplexes based on cationic polymers with strong nucleic acid binding properties. Eur J Pharm Sci 45:459-466
243. Venturini L, Battmer K, Castoldi M et al (2007) Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109:4399-4405
244. Vickers TA, Wyatt JR, Burckin T et al (2001) Fully modified 2’ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 29:1293-1299
245. Villalona-Calero MA, Ritch P, Figueroa JA et al (2004) A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 10:6086-6093
246. Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261
247. Wang Z (2011) The concept of multiple-target anti-miRNA antisense oligonucleotide technology. Methods Mol Biol 676:51-57
248. Wang J, Chen P, Mrkobrada M et al (2003) Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. Eur J Nucl Med Mol Imaging 30:1273-1280
249. Wang Y, Decker SJ, Sebolt-Leopold J (2004) Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3:305-313
250. Wang Y, Ngo VN, Marani M et al (2010) Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 29:4658-4670
251. Weidle UH, Maisel D, Eick D (2011) Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genomics Proteomics 8:159-171
252. Whitehurst AW, Bodemann BO, Cardenas J et al (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819
253. Whitehurst AW, Xie Y, Purinton SC et al (2010) Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 70:7652-7661
254. Wilson DM 3rd, Simeonov A (2010) Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci 67:3621-3631
255. Wu H, Lima WF, Zhang H et al (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279:17181-17189
256. Yang D, Liu H, Goga A et al (2010) Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 107:13836-13841
257. Yaron PN, Holt BD, Short PA et al (2011) Single wall carbon nanotubes enter cells by endocytosis and not membrane penetration. J Nanobiotechnology 9:45
258. Yin H, Betts C, Saleh AF et al (2010) Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther 18:819-827
259. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27:6398-6406
260. Yu RZ, Geary RS, Leeds JM et al (2001) Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90:182-193
261. Zaghloul EM, Viola JR, Zuber G et al (2010) Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine. Mol Pharm 7:652-663
262. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280-284
263. Zellweger T, Miyake H, Cooper S et al (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2’-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934-940
264. Zellweger T, Kiyama S, Chi K et al (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 92:463-469
265. Zhang G, Budker V, Williams P et al (2001) Efficient expression of naked dna delivered intraarterially to limb muscles of nonhuman primates. Hum Gene Ther 12:427-438
266. Zhang X, Dong X, Sawyer GJ et al (2004a) Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J Gene Med 6:693-703
267. Zhang Z, Wang H, Prasad G et al (2004b) Radiosensitization by antisense anti-MDM2 mixed- backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10:1263-1273
268. Zhou T, Jia X, Li H et al (2011) New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo. Int J Nanomedicine 6:1527-1534